Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zintevir
- Development stage
- Phase 1
- Lead developer
- Agenus
- Modality
- Small Molecules, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
Zintevir is a 17-mer oligonucleotide analogue with phosphorothioate modifications at both termini, designed to form a potassium-induced quadruplex structure. It was developed as an anti-HIV agent and is among the first oligonucleotides to enter human clinical trials for HIV infection. Initially described as an HIV integrase inhibitor, subsequent studies indicate its primary mechanism of action involves binding to the viral gp120 envelope protein, thereby inhibiting virus binding or fusion with host cells. Zintevir demonstrated potent anti-HIV activity *in vitro* and advanced into Phase I/II clinical trials but was ultimately discontinued from further development[1][2][3][4][5].
- Brand names
- Zintevir
- Other names
- AR177AR-177AR 177T30177T-30177T 30177
02
Targets
gp120 C5 (HIV-1 gp120 C5 domain)
Beyond the preview
Go deeper on Zintevir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zintevir.